Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The potential of DAOs for funding and collaborative development in the life sciences.

Nature biotechnology·2024
Same author

An overview of Fintech applications to solve the puzzle of health care funding: state-of-the-art in medical crowdfunding.

Financial innovation·2022
Same author

Physician perceptions of drug utilization management: Results of a national survey.

PloS one·2022
Same author

Examining insurance companies' use of technology for innovation.

The Geneva papers on risk and insurance. Issues and practice·2021
Same journal

Blockchain Technology to Enhance Clinical Data Management in Healthcare: A Systematic Literature Review.

Blockchain in healthcare today·2026
Same journal

Design and Development of a Blockchain-Based System to Protect Medical Records.

Blockchain in healthcare today·2026
Same journal

Zero-Knowledge Process Verification: A Comprehensive Framework for a Distributed Healthcare System.

Blockchain in healthcare today·2026
Same journal

Why We Don't Use Guest Editors: A Publisher's Perspective.

Blockchain in healthcare today·2026
Same journal

Blockchain-Enabled Electronic Health Record Model for Managing Patients' Vital Data and Medical Reports.

Blockchain in healthcare today·2026
Same journal

Blockchain Applications in Core Healthcare Services: Patient Data, Research, and Institutional Processes.

Blockchain in healthcare today·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

Innovating Pharma: Bridging Traditional Acquisition and Emerging Technologies.

Simone Fantaccini1, Laura Grassi2, Scott Howell3

  • 1Independent.

Blockchain in Healthcare Today
|May 28, 2026
PubMed
Summary
This summary is machine-generated.

Large pharmaceutical companies are exploring decentralized technologies like blockchain and DAOs to enhance merger, acquisition, and partnership strategies. While promising for innovation, integration faces hurdles like legal ambiguity and governance rigidity.

Keywords:
DAOM&Aacquisitionblockchainfintechlarge-cap pharmaceutical companymergers and acquisitionspharmaceutical corporationtoken

More Related Videos

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Development of New Therapeutic Applications Using Microfluidics
08:56

Development of New Therapeutic Applications Using Microfluidics

Published on: October 1, 2007

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

Area of Science:

  • Pharmaceutical industry innovation
  • Decentralized technologies in business
  • Mergers and acquisitions strategy

Background:

  • Large pharmaceutical corporations face evolving innovation landscapes.
  • External sourcing and partnerships are crucial for pipeline sustainability.
  • Emerging technologies offer new avenues for R&D and collaboration.

Purpose of the Study:

  • To explore the integration of decentralized technologies (blockchain, DAOs) into pharmaceutical M&A and partnership frameworks.
  • To understand how these technologies intersect with innovation and external sourcing models.
  • To analyze the strategic implications for large pharmaceutical companies.

Main Methods:

  • Qualitative case study methodology.
  • Document analysis and semi-structured interviews with internal stakeholders.
  • Focus on strategy alignment, organizational attitudes, integration constraints, and innovation value.

Main Results:

  • Acquisition and innovation strategy driven by long-term alignment of external opportunities and internal priorities.
  • Increased reliance on external innovation sources, leveraging technology for scouting and forecasting.
  • Decentralized technologies (DAOs) show promise for early innovation but face integration challenges (legal, governance, economics).
  • M&A and licensing remain critical; emerging tech can accelerate preclinical decisions and ecosystem visibility.

Conclusions:

  • Large pharmaceutical firms can adapt innovation models using digital and decentralized technologies.
  • Established M&A and partnership mechanisms remain dominant.
  • Decentralized technologies offer complementary tools for scouting, collaboration, and portfolio expansion.